High BP pills can also reduce colorectal cancer risk | WeForNews | Latest News, Blogs High BP pills can also reduce colorectal cancer risk – WeForNews | Latest News, Blogs
Connect with us

Health

High BP pills can also reduce colorectal cancer risk

“Our results provide new insights on a potential role of these medications for colorectal cancer prevention,” said study author Wai K Leung from the University of Hong Kong in Hong Kong.

Published

on

Arm Blood Pressure Pulse Monitor

Hong Kong, July 6 : Researchers have now claimed that medications commonly prescribed to treat high blood pressure may also reduce patients’ colorectal cancer risk.

Angiotensin converting enzyme inhibitor (ACE-i) or angiotensin II receptor blocker (ARB) medications are prescribed for conditions such as heart failure, high blood pressure or heart disease. These medications inhibit or block angiotensin, a chemical that causes arteries to become narrow, the researchers said.

Doctors commonly prescribe these medications to people with high blood pressure to relax and open blood vessels, thereby lowering blood pressure.

The current study, published in the Hypertension, an American Heart Association journal, revealed that taking these medications may also reduce colorectal cancer risk.

“Our results provide new insights on a potential role of these medications for colorectal cancer prevention,” said study author Wai K Leung from the University of Hong Kong in Hong Kong.

“This is the first study to show the potential beneficial effects of ACE inhibitors and ARBs on colorectal cancer development, based on a large group of patients who were colorectal cancer-free at the beginning of the study,” Leung added.

The roles of ACE inhibitors and ARBs on cancer development are controversial and, in some cases, study findings are conflicting. Results of previous studies have been limited by several factors including a small number of patients and data only on short-term follow-ups.

For the present study, the research team reviewed health records of 187,897 adult patients in Hong Kong from 2005 to 2013, with a negative baseline colonoscopy for colorectal cancer. The analysis found that those who took hypertension medications such as ACE-i or ARBs had a 22 per cent lower risk of developing colorectal cancer in the subsequent three years.

The benefits of ACE-i and ARBs were seen in patients 55 or older and those with a history of colon polyps and the benefit associated with the medications were limited to the first three years after the negative baseline colonoscopy.

“While ACE-i and ARBs are taken by patients with high blood pressure, heart failure and kidney diseases, the reduction in colorectal cancer risk may be an additional factor for physicians to consider when choosing anti-hypertensive medications,” Leung said.

Researchers noted that the results should be verified with a prospective randomised controlled study, which would actively follow patients to determine the potential benefits of these medications on colorectal cancer risk.

Health

PGI-Chandigarh among 17 trial sites for Oxford vaccine Covishield

The permission was granted after the Serum institute satisfied certain requirements sought by the Drug Controller in the design of the proposal.

Published

on

By

Covid 19 Vaccine

Chandigarh, Aug 4 : The PGI Hospital here is among the 17 trial sites in India for conducting the second and third phases of human clinical trials of Covishield, the potential vaccine developed by Oxford University, its director said on Tuesday.

The trials would involve administration of the vaccine to 1,600 healthy adults across 17 sites.

Postgraduate Institute of Medical Education and Research (PGIMER) Director Jagat Ram said, “It’s an honour to be entrusted with this vital responsibility of being one of the sites for phase two and three trials on Covishield vaccine.

“The results of phase one trials in the UK have been encouraging and did not present any serious adverse side effects. Phase two and three trials will be done on a larger human population to see its efficacy and requisite protection against COVID-19 in humans.”

Further detailing, the Director added, “As the results of the trials will have far reaching impact, we will strengthen our capacities, wherever required, to come out with tangible outcomes.

“A core group will be constituted to work out the modalities and comprehensive plan along with timelines to meet the desired expectations of Drugs Controller General of India and contribute towards containing the pandemic to the best of our abilities.”

Earlier, a committee of experts on COVID-19 under Central Drugs Standard Control Organisation (CDSCO) had recommended the Drugs Controller General of India (DCGI) to grant approval to the Serum Institute of India (SII) for conducting the Phase two and three trials.

The permission was granted after the Serum institute satisfied certain requirements sought by the Drug Controller in the design of the proposal.

In addition to PGIMER Chandigarh, the other sites for trials include AIIMS in Delhi, ABJ Medical College in Pune, Rajendra Memorial Research Institute of Medical Sciences (RMRIMS) in Patna, AIIMS in Jodhpur, Nehru Hospital in Gorakhpur, Andhra Medical College in Visakhapatnam and JSS Academy of Higher Education and Research in Mysuru.

Continue Reading

Disaster

COVID-19 pandemic “once in a century”, but still “in our hands”: WHO

“I’m not saying there is no solution now. Whatever happens in the next few months or years, I also believe that it’s in our hands,” he said.

Published

on

By

Tedros Adhanom Ghebreyesus WHO

Geneva, Aug 4 : The chief of the World Health Organization (WHO) said that the COVID-19 pandemic is “a once-in-a-century health crisis,” but it is still “in our hands.”

WHO Director-General Tedros Adhanom Ghebreyesus said at a virtual press conference on Monday that the world has never seen anything like this pandemic for decades, and its effects might last for decades more, Xinhua news agency reported.

“Since we started probably recording, this is the first ever coronavirus-caused pandemic which has two dangerous combinations: it moves fast, and at the same time it’s a killer,” the WHO chief explained.

However, he noted, although the crisis is very severe, there are still solutions and hopes.

“I’m not saying there is no solution now. Whatever happens in the next few months or years, I also believe that it’s in our hands,” he said.

“Since the outbreak started, many countries have shown that it can be controlled, or serious transmission can be suppressed,” Tedros said, adding that he has mentioned many such countries in the past, including Spain, Italy, China and South Korea.

Continue Reading

Cities

Delhi govt bans use of hookah in hotels, restaurants to stem COVID-19 spread

Delhi has so far recorded 1,38,482 COVID-19 cases and 4,021 people have died due to the disease.

Published

on

hookah bar

New Delhi, Aug 3 : The Delhi government on Monday banned the use of hookahs, with or without tobacco, in all public places, including hotels, restaurants and bars, with immediate effect to control the spread of COVID-19.

Smokers are likely to be more vulnerable to COVID-19 as smoking means the fingers are in contact with the lips which increases the possibility of transmission of the virus, the health department said in an order.

“Smokers may also already have lung diseases or reduced lung capacity which would greatly increase the risk of serious illness,” it said.

Smoking products such as water pipes often involve the sharing of mouthpieces and hoses, which could facilitate the transmission of COVID-19 in communal and social settings, the health department said.

Therefore, the use and sharing of hookah, with or without tobacco (herbal hookah), “which might further increase the spread of SARS-CoV2, is strictly prohibited in all public places, including hotels, restaurants, bars, pubs, eateries, discotheques, etc. in Delhi with immediate effect to prevent and control the outbreak of COVID-19”, it said.

Delhi has so far recorded 1,38,482 COVID-19 cases and 4,021 people have died due to the disease.

Continue Reading
Advertisement

Most Popular

Corona Virus (COVID-19) Live Data

COVID-19 affects different people in different ways. Most infected people will develop mild to moderate illness and recover without hospitalization.